%0 Journal Article
%A Teuwen, Laure-Anne
%A De Rooij, Laura P M H
%A Cuypers, Anne
%A Rohlenova, Katerina
%A Dumas, Sébastien J
%A García-Caballero, Melissa
%A Meta, Elda
%A Amersfoort, Jacob
%A Taverna, Federico
%A Becker, Lisa M
%A Veiga, Nuphar
%A Cantelmo, Anna Rita
%A Geldhof, Vincent
%A Conchinha, Nadine V
%A Kalucka, Joanna
%A Treps, Lucas
%A Conradi, Lena-Christin
%A Khan, Shawez
%A Karakach, Tobias K
%A Soenen, Stefaan
%A Vinckier, Stefan
%A Schoonjans, Luc
%A Eelen, Guy
%A Van Laere, Steven
%A Dewerchin, Mieke
%A Dirix, Luc
%A Mazzone, Massimiliano
%A Luo, Yonglun
%A Vermeulen, Peter
%A Carmeliet, Peter
%T Tumor vessel co-option probed by single-cell analysis.
%D 2021
%U https://hdl.handle.net/10668/27805
%X Tumor vessel co-option is poorly understood, yet it is a resistance mechanism against anti-angiogenic therapy (AAT). The heterogeneity of co-opted endothelial cells (ECs) and pericytes, co-opting cancer and myeloid cells in tumors growing via vessel co-option, has not been investigated at the single-cell level. Here, we use a murine AAT-resistant lung tumor model, in which VEGF-targeting induces vessel co-option for continued growth. Single-cell RNA sequencing (scRNA-seq) of 31,964 cells reveals, unexpectedly, a largely similar transcriptome of co-opted tumor ECs (TECs) and pericytes as their healthy counterparts. Notably, we identify cell types that might contribute to vessel co-option, i.e., an invasive cancer-cell subtype, possibly assisted by a matrix-remodeling macrophage population, and another M1-like macrophage subtype, possibly involved in keeping or rendering vascular cells quiescent.
%K anti-angiogenic therapy
%K cancer cells
%K endothelial cells
%K macrophages
%K metastasis
%K pericytes
%K resistance
%K single-cell RNA sequencing
%K tumor angiogenesis
%K tumor vessel co-option
%~